Get In Touch
Have any questions or comments about the content you see on this page?
May 1, 2020
Our CEO John Maraganore recently spoke with Biotechnology Innovation Organization (BIO) CEO and Chairman Jim Greenwood on the "I Am BIO" podcast. John and Jim spoke about RNAi therapeutics as an innovative new class of medicines, Alnylam's pipeline and our development program targeting SARS-CoV-2, the virus causes COVID-19. He discusses why we believe that RNAi presents a potentially novel and powerful therapeutic approach to treating and preventing COVID-19 infection and the origins of our COVID-19 collaboration with our partner Vir Biotechnology. You can learn more about the latest developments in our COVID-19 program here.
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.Proceed to Site